Imunon to host R&D day spotlighting Phase 3 OVATION 3 trial for IMNN-001 in ovarian cancer
IMNN•Investor R&D day set for Sept. 23 in New York
Imunon will host an investor R&D Day on Sept. 23, 2026, in New York City.
The event will focus on the Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
Presentations will cover recent clinical developments, trial progress, upcoming milestones, and Phase 2 MRD work with Break Through Cancer.
